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Summary We report a phase I/II study of the indole derivative, zindoxifene, an anti-oestrogen with intrinsic
oestrogenic activity. We have treated 28 women with advanced breast cancer of whom 26 had received prior
endocrine therapy. Oral zindoxifene doses ranged from 10 to 100 mg daily; doses were escalated in some
patients. Twenty-five patients were assessed for response; the remaining three patients completed less than 3
weeks of treatment. There were no objective responses; disease stabilised in seven patients for up to 5 months
and progressed in the remaining 18. Five patients (including three treated with tamoxifen) responded to
subsequent endocrine therapy. Nausea, which was dose-limiting, affected half of the patients treated with
80 mg daily. Metabolites of zindoxifene were detectable in serum at all doses used, and sex hormone binding
globulin (SHBG) levels showed a strong tendency to rise at the higher doses, indicating that zindoxifene is
absorbed and has biological activity. We conclude that zindoxifene in the doses used in this study has only
marginal therapeutic activity in the treatment of advanced breast cancer.
Anti-oestrogens are widely used in the treatment of breast
cancer. Approximately 60% of breast carcinomas contain
measurable quantities of oestrogen receptor (ER), of which
half will respond to tamoxifen, which is the only anti-
oestrogen in widespread clinical use in the treatment of
breast cancer (McGuire, 1978; Mourisden et al., 1978). Res-
ponse to endocrine treatment in breast cancer is of limited
duration. Relapse is not associated with the conversion of
tumours from being ER positive to negative (Taylor et al.,
1982). It is possible that the ER in relapsed or non-res-
ponsive tumours has reduced biological activity. Tamoxifen
is a weak anti-oestrogen with some partial agonistic actions
(Jordan, 1984). The properties of the ideal anti-oestrogen
have not been established. It is possible that an improved
response rate and response duration might be achieved by
treatment with a purer anti-oestrogen than tamoxifen. There
is evidence, however, that the oestrogen agonist properties of
tamoxifen contribute to its therapeutic effect (Hartmann,
1983). Compounds with a different balance of oestrogen
antagonist and agonist activities to tamoxifen should be
investigated for therapeutic activity in breast cancer.
Zindoxifene (Dl 6726) is an acetylated indole derivative
which is hydrolytically cleaved to release a dihydroxy-indole
(Dl5414) with a high affinity for the ER (Von Angerer,
1984). The compound has oestrogen antagonist and agonist
properties, and has been shown to be effective in the treat-
ment of rat DMBA induced mammary carcinomas (Von
Angerer, 1984; Von Angerer et al., 1985; Hilgard et al.,
1988). In this paper we report a phase I/II study of zindox-
ifene in advanced human breast cancer.
Zindoxifene was evaluated as part of a co-ordinated pro-
gramme under the aegis of the Cancer Research Campaign
Phase I/II Clinical Trials Committee.
Patients and methods
Twenty-eight post-menopausal women with histologically or
cytologically proven locally advanced or metastatic breast
cancer were treated with zindoxifene between July 1986 and
September 1988. The age range of patients was 48-90 years
(median 64). Eight patients were known to have ER positive
carcinomas, five had ER negative carcinomas and the ER
status of 15 was unknown. Twenty-six patients had received
previous endocrine therapy of whom 15 had responded.
Twelve of the previously treated patients had received tamox-
ifen either alone or in combination with other agents (two
patients), of whom seven had responded. All patients had
discontinued previous treatments at least 3 weeks before
entry and had progressive disease on entry.
Full staging, consisting of clinical examination, measure-
ment of blood count, serum calcium and liver function tests,
chest radiograph, isotope bone scan, radiographic limited
skeletal survey and liver ultrasound was performed on entry,
after 3 months of treatment and on completion of treatment.
Clinical examination, measurement of blood count and liver
function tests, and toxicity assessment were repeated at least
monthly. Assessments of response were made according to
standard UICC criteria (Hayward et al., 1977).
Zindoxifene (Dl6726, ASTA Pharma AG, Clinical Cancer
Research, Bielfeld, FRG) was supplied in 10mg and 20mg
capsules. Consecutive groups of three patients were given
starting doses of 10 mg, 20 mg, 30 mg, 40 mg and 60 mg
daily. At 60 mg daily oestrogenic effects were observed and
for this reason eight more patients (i.e. 11 in total) were
treated at this dose. Because of satisfactory tolerance, a
further five patients were treated at 80 mg daily. Zindoxifene
dose was variably escalated in a proportion of patients,
especially in those who started treatment with the lower
doses. The total number of patients receiving treatment at
each dose level was as follows: 10 mg, 3; 20 mg, 5; 30 mg, 4;
40mg, 7; 60mg, 16; 80mg, 8; 100mg, 2.
Blood was taken for endocrine assessment prior to and
during zindoxifene treatment; serum oestradiol, gonado-
trophins and sex hormone binding globulin (SHBG) levels
were measured using previously published assays (Ferguson
et al., 1982; Dowsett et al., 1985, 1987).
Serum levels of zindoxifene and its metabolites were mea-
sured by high performance liquid chromatography with
fluorimetric detection (minimum quantifiable level
0.1 tmol 1'). The assay has previously been published (Birn-
bock et al., 1987). The within and inter-assay coefficients of
variation were 3% and 7% respectively. Serum samples were
stored at - 20°C until analysed. Metabolites (glucuronide
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and sulphate) of zindoxifene were measured by enzymatic
cleavage with both glucuronidase and aryl-sulphatase to
D15414 before analysis.
Results
Twenty-five patients were assessed for a response to zindox-
ifene treatment. Three patients who were treated for less than
3 weeks, one because of life threatening disease and two
because of drug intolerance, were considered ineligible for
response assessment. All remaining patients were treated
until disease progression. Disease stabilisation occurred in
seven patients for between 2 and 5 months during zindox-
ifene treatment; the remaining 18 patients had progressive
disease. No patient had an objective response to zindoxifene.
Sixteen patients received further endocrine treatment after
zindoxifene of whom five patients, including three out of six
treated with tamoxifen (at 20 mg daily), had partial res-
ponses.
Toxicity data is available for all 28 patients. Side-effects
were mostly mild. The most commonly experienced side
effect was mild to moderately severe nausea which affected 11
patients, including five of the 16 patients treated with 60 mg
daily, four of the eight treated with 80 mg daily and one of
the two treated with 100 mg daily. Although the nausea
experienced by some patients was multifactorial in origin, the
symptoms improved in all cases on dose reduction or discon-
tinuation of therapy. Nausea was controllable with
antiemetics in the majority of cases. Treatment was discon-
tinued in two patients as a result of nausea and the dose was
reduced in a further three. In addition, two patients com-
plained of constipation, one of dry mouth, one of sore mouth
and one of lethargy. Two patients (one of whom was
recovering from hip surgery at the time) had a deep venous
thrombosis whilst being treated with zindoxifene.
Endocrine data are available for 17patients. Serum SHBG
levels did not change significantly in patients treated with
10-40 mg of zindoxifene daily. At the 60 mg daily dose,
SHBG levels doubled in six out of 10 patients. The effect
of zindoxifene dose on SHBG levels is shown in Figure 1.
The mean (± s.e.m.) SHBG level for all patients
was 80.1 ±10.0 nmol
1' pretreatment, rising to
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Figure 1 Percentage change (geometric mean ± 95% confidence
interval of the mean) of SHBG levels at different doses of zindox-
ifene. SHBG levels were measured after 1-3 weeks of continuous
daily zindoxifene treatment at the dose indicated.
130.8 ± 15.2 nmol 1' after 2 (range 1-3) weeks of treatment
with zindoxifene at a median dose of 60 mg daily (P< 0.001,
Student's t test for paired samples).
LH and FSH levels did not fall significantly as a result of
zindoxifene treatment, even at the 60 mg daily dose. The
pretreatment and on treatment means (measured at the same
time as SHBG levels) were for LH, 29.7 ± 4.1 and
26.1+4.3 IU 1-', and for FSH, 35.9 ± 5.4 and
27.1 ± 5.0 IU1', respectively. Serum oestradiol levels
(23.7 ± 4.8 pmol 1' pretreatment, 19.3 ± 4.6 pmol 1' on
treatment) were not significantly affected by zindoxifene
treatment either.
Serum zindoxifene levels were measured at at least one
point during treatment in 16 patients. No zindoxifene
(D16726) or free hydroxy-indole (DI5414) compounds were
detected. D15414 was detectable after enzymatic cleavage of
glucuronide and sulphate metabolites. The mean (and range)
of total metabolite levels measured in 10 patients on chronic
medication between 2 and 6 h after dosing varied according
to zindoxifene dose as follows: 10 mg, 66.8 (50.0-83.5);
20mg, 89.0 (27.0-155.0); 30mg, 144.0 (30.0-258.0); 60mg,
350.0 (213.7-636.0) jig1`. (Values are the mean of 2-4
determinations from each of 2-4 patients at each dose level.)
Multiple measurements of metabolite levels were made in six
patients over a 24 h period following a single dose of
10-40 mg of zindoxifene. Peak levels were detected between
2 and 5 h after dosing in the majority of patients. Levels had
fallen to between 18 and 38% (median 26%) of peak levels
24 h after dosing.
Discussion
We have reported the first study of oral zindoxifene in the
treatment of patients with advanced breast cancer. The lack
of efficacy of zindoxifene in our study is disappointing in
comparison to the reported activity of the compound in
preclinical studies (Von Angereret al., 1985; Hilgardet al.,
1988). None of the 25 patients who were eligible for response
assessment had tumour regression as a result of zindoxifene
treatment. Because of the phase I nature of the study, a
number of patients were included who were relatively un-
likely to respond to zindoxifene. These included five patients
with ER negative carcinomas. Twelve patients who had
previously received tamoxifen and might thus be considered
less likely to respond to a second anti-oestrogen than patients
without prior exposure to tamoxifen were also entered. The
majority of the remaining patients had either previously res-
ponded to aromatase inhibitor treatment or had ER positive
carcinomas and were therefore likely to have hormonally
responsive disease. Although the inclusion of patients with a
low probability of response to zindoxifene in the study
reduced the likelihood of demonstrating activity of the com-
pound, the complete absence of responders makes it unlikely
that zindoxifene has useful activity in the treatment of breast
cancer. On completion of zindoxifene treatment, 16 patients
were considered suitable for further endocrine therapy. It is
significant that five of these patients responded to treatment,
including three of the six who were given tamoxifen.
Circulating zindoxifene metabolites have been detected at
all dose levels used. The measured rise in SHBG levels at the
higher doses of zindoxifene implies that sufficient drug is
absorbed to have a biological effect. The significance of the
rapid metabolism of zindoxifene is not understood. Although
similar metabolism occurs in the rat, low levels of circulating
free drug have been detected in that species, in contrast to
humans (Birnbocket al., 1987). It is possible that the
difference in metabolism of the active free drug, Dl 5414,
between humain and rat, although small, is sufficient to ex-
plain the different clinical results in the two species.
Serum SHBG levels showed a strong tendency to rise at
the higher doses of zindoxifene used. A similar rise in SHBG
levels with an associated fall in gonadotrophin levels in
patients treated with tamoxifen has been attributed to the
partial oestrogen agonist activity of tamoxifen (Sakaiet al.,
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1978; Willis et al., 1977; Coombes et al., 1982; Dowsett et al.,
1984). We have not observed a fall in gonadotrophin levels in
zindoxifene treated patients. Since the compound is given
orally, its effect on hepatic function (including SHBG syn-
thesis) would be expected to be greater than its systemic
activity, especially if this is reduced as a result of hepatic
conjugation. This may explain the lack of a significant
change in gonadotrophin levels despite the oestrogenic effect
on SHBG levels. It is possible that zindoxifene has a pre-
dominantly oestrogenic rather than anti-oestrogenic action in
humans, while at the same time failing to possess sufficient
oestrogenic potency to induce tumour regression at the doses
used. Recently reported in vitro studies using human cell lines
support this interpretation (Robinson et al., 1988). The lack
of effect of zindoxifene on gonadotrophin levels (in contrast
to that of tamoxifen) suggests that the in vivo oestrogenic
activity of the compound is low, possibly as a result of
hepatic metabolism. It would be interesting to compare the
dose related oestrogenic effects of tamoxifen and zindoxifene.
Unfortunately we have insufficient data to allow that in the
current study.
Due to the phase I nature of the study, it is difficult to be
certain that patients were treated with an optimal dose of
zindoxifene, despite the variable dose escalation that we used.
Nausea, which affected 50% of patients treated with 80 mg
daily, precluded dose escalation above that level. Experimen-
tal studies in the rat, comparing zindoxifene to tamoxifen,
suggest that both drugs should be equipotent at equimolar
doses (Hilgard et al., 1988). Doses as low as 20 mg daily
could be expected to be active. Because of the dose escala-
tions used in the current study, a minority of patients were
treated for brief periods only with these low doses. It remains
possible that we may have failed to demonstrate a thera-
peutic action of zindoxifene at the lower end of the dose
range, although loss of therapeutic activity with increasing
dose has not been described in the case of tamoxifen.
Tamoxifen is known to have a number of actions, such as
inhibition of protein kinase-C and calmodulin, promotion of
phospho-inositide hydrolysis and interaction with some
classes of histamine, dopamine and acetylcholine receptors at
the cell membrane, which are not mediated by interaction
with the ER (Weiss et al., 1988). Some of the non-genomic
actions of tamoxifen may contribute to its activity in breast
cancer and it may be that zindoxifene, an indole derivative
which is structurally dissimilar to other anti-oestrogens, lacks
such actions, accounting for some of its poor activity in
breast cancer.
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